The risk of aspiration under anesthesia is real and potentially life-threatening
Industry analysts suggest that the introduction of FDA-approved oral GLP-1 medications may shift competitive dynamics within the weight loss treatment market
A new study suggests people taking popular injected medications for weight loss, including Wegovy, Ozempic, Saxenda and Victoza, may be at higher risk for serious digestive problems such as stomach paralysis, pancreatitis, and bowel obstructions, compared with those taking other types of weight loss medications
Regarding pancreatitis, other data have argued that, Switching between GLP-1 agonists may increase the risk of adverse effects, especially if dose titration protocols are not followed. Noteworthy: Other studies have found that semaglutide and tirzepatide may actually decrease the risk of recurrent acute pancreatitis. Above all, if you suspect you may be developing pancreatitis, consult with your doctor right away, who will likely advise you to stop taking the medication
Never adjust your Wegovy dose without medical guidance, as this may affect both efficacy and safety